Effect of priming with carrier on response to conjugate vaccine.

Lancet
D Di JohnM M Levine

Abstract

To examine whether prior immunity against a carrier protein modulates the serological response to injected peptide haptens attached to the same carrier in man, baseline tetanus antitoxin levels in volunteers who received a malaria sporozoite peptide-tetanus toxoid conjugate vaccine were compared with post-vaccination IgM and IgG antibody titres against the sporozoite antigen. In tetanus-vaccinated North American recipients of low doses of conjugate vaccine there were significant dose-dependent negative correlations between these variables, which suggests that epitopic suppression may occur in man. In contrast, Venezuelans living in non-malarious areas and mostly naive to tetanus toxoid showed a notable IgM response to the sporozoite antigen. The findings indicate that epitopic suppression and immune enhancement occur in man, and that the specific immunological responses to conjugate peptide vaccines may be difficult to predict.

References

Jun 1, 1969·The Journal of Experimental Medicine·K RajewskyN K Jerne
Jun 26, 1980·Nature·L A HerzenbergL A Herzenberg
Jun 1, 1965·Proceedings of the Society for Experimental Biology and Medicine·H ASHLEY, Z OVARY

❮ Previous
Next ❯

Citations

May 1, 2010·Biotechnology Letters·Pieranna ChiarellaArio de Marco
Feb 1, 1992·Immunology Today·H M Etlinger
Jul 26, 2005·International Immunopharmacology·Imed Ben NasserDaniel Tome
May 20, 2004·Vaccine·D BogaertR de Groot
Oct 3, 1999·Vaccine·D C JacksonW Zeng
Oct 3, 1999·Vaccine·A A Lindberg
Jan 26, 2000·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·A A Lindberg
Aug 8, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jin Hyang KimJoshy Jacob
Aug 1, 1990·Scandinavian Journal of Immunology·J I Elliott
May 31, 1995·Annals of the New York Academy of Sciences·H M Etlinger
Aug 23, 2005·Infection and Immunity·Karin BaraldoGiuseppe Del Giudice
Jul 23, 2015·ACS Applied Materials & Interfaces·Suttipun SungsuwanXuefei Huang
Apr 13, 2000·Pediatric Clinics of North America·M E Pichichero
Jan 1, 1990·International Reviews of Immunology·R Edelman, C O Tacket
Dec 1, 1995·European Journal of Immunology·A KaliyaperumalR Raghupathy
Apr 6, 2018·PLoS Pathogens·Barbara SchlingmannMartin L Moore
Oct 12, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·C O TacketM M Levine
Jun 13, 2001·Biochemical and Biophysical Research Communications·S GonzálezR Pajón
Oct 1, 1991·Infection and Immunity·C C PeetersG T Rijkers
Apr 21, 2006·Analytical Biochemistry·Lilian R TsurutaOsvaldo A Sant'Anna
Mar 20, 2013·ACS Chemical Biology·Zhaojun YinXuefei Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.